#USA #pancreatic cancer #Plymouth Meeting #Health Disparities #JNCCN

Unequal Treatment: New Research on Pancreatic Cancer Disparities

A groundbreaking study published in the April 2025 edition of the Journal of the National Comprehensive Cancer Network (JNCCN) sheds light on severe disparities in treatment and survival rates among patients diagnosed with metastatic pancreatic cancer, particularly affecting socially vulnerable populations. Conducted by researchers at the Wexner Medical Center and the James Comprehensive Cancer Center at The Ohio State University, this investigation underscores the urgent need for reforms in oncology care to address these inequities.

The researchers analyzed data from 14,147 patients diagnosed with metastatic pancreatic ductal adenocarcinoma (mPDAC) between 2005 and 2019 using the SEER-Medicare database. The findings revealed disturbing trends based on factors like race, socioeconomic status, and other social determinants of health. Notably, patients exhibiting higher levels on the Social Vulnerability Index (SVI) were found to be 30% less likely to receive essential quality indicators of care, which include:

1. Adherence to systemic therapy guidelines
2. Access to palliative care
3. Survival rates exceeding 12 months

The study highlighted that individuals from disadvantaged racial or ethnic groups were 25% less likely to receive one or more indicators of high-quality care, even when controlling for income levels. Furthermore, a lower socioeconomic level corresponded to a 34% decrease in the likelihood of experiencing at least one quality indicator, independent of race.

Dr. Diamantis Tsilimigras, the lead author, emphasized the pressing need for targeted interventions to alleviate disparities in cancer care. He pointed out that federal policies aimed at expanding Medicaid or potentially enhancing Medicare coverage for palliative services could be impactful in bridging these gaps. Additionally, addressing social determinants of health and providing financial aid to the most vulnerable populations is essential for fostering equitable healthcare access.

The study also indicated that those who received appropriate systemic or palliative care had better-than-average survival rates after the initial diagnosis of mPDAC. Over the study's timeframe, improvements were noted in both quality assessments and patient longevity. Dr. Timothy M. Pawlik, another lead author on the study, remarked that while compliance with NCCN guidelines has increased, significant disparities remain in the receipt of guideline-concordant care, which ultimately influences patient outcomes.

Expert commentary from Dr. Jason S. Gold of Harvard Medical School, who did not participate in the study, echoed these findings, stating that the existing inequalities in pancreatic cancer treatment and outcomes are increasingly recognized. His insights reveal how social vulnerability, being unmarried, and lower income levels are independently linked to inferior quality of care.

In conclusion, the study calls for heightened awareness and action among healthcare practitioners, policymakers, and the public to rectify these care disparities in metastatic pancreatic cancer. The full study, titled “Quality Score Among Patients With Metastatic Pancreatic Adenocarcinoma Trends, Racial Disparities, and Impact on Outcomes,” along with Dr. Gold's commentary, is available in the April 2025 edition of JNCCN.

For further reading and resources, visit JNCCN.org. This peer-reviewed journal serves over 25,000 oncology professionals across the U.S., providing the latest insights and updates on quality care and research in cancer treatment. The National Comprehensive Cancer Network (NCCN), of which JNCCN is a part, is dedicated to improving cancer prevention and care, ensuring that quality health remains accessible to all.

Explore more on how these findings could prompt changes in policy and clinical practice to support equitable healthcare services for those affected by pancreatic cancer.